Facility Dedicated to Cryopreservation of
Leukapheresis Starting Materials to Support Clinical and Commercial
Cell-Based Therapy Programs
NASHVILLE, Tenn., Nov. 12,
2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX)
("Cryoport" or the "Company"), a global leader in supply chain
solutions for the life sciences industry, today announced the
opening of its newest IntegriCell™ facility in Villers-le-Bouillet,
Liege, Belgium. The Center of
Excellence is now fully operational and prepared to support the
development and commercialization of cell-based therapies with
advanced cryopreservation solutions for leukapheresis, a common
starting material.
IntegriCell is a standardized bioprocessing, cryopreservation
and distribution solution for the global cell therapy market. The
solution is designed to enhance cell therapy manufacturing
efficiency and flexibility, ensuring safety, quality and product
stability to support the effective scale up, production and
availability of these lifesaving treatments to an expanding number
of patients.
This ~1,300 square meter (~13,400 sq. ft.), custom-built,
GMP-compliant cryopreservation facility expands Cryoport's
capabilities by developing, optimizing and validating cryogenic
preservation methods for leukapheresis materials to meet the
highest standards for cell-based therapies. The facility has the
capacity to cryopreserve over 1,100 leukapheresis products
annually. IntegriCell will provide a reliable supply of
high-quality, manufacture-ready cryopreserved leukopaks. As
Cryoport Systems' European Center of Excellence, the IntegriCell
Belgium site will transfer these optimized cryopreservation
processes to other Cryoport facilities, ensuring consistent quality
across clinical and commercial cell-based therapy programs.
"Our new IntegriCell Belgium facility extends our global reach
and strengthens our ability to deliver consistent, high-quality
cryopreservation solutions for the cell therapy community," said
Jerrell Shelton, CEO of Cryoport.
"This Center of Excellence, together with our Houston, TX facility, provides the industry
with a critical resource to standardize and improve how we preserve
cellular starting materials, helping bring transformative therapies
to patients more efficiently. With room for future expansion, this
facility is designed to adapt and expand with our clients' and the
market's evolving needs."
Details on the IntegriCell Belgium facility grand opening event
will be shared through Cryoport's social media channels in the
upcoming weeks.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is
a global leader in supply chain solutions for the Life Sciences
with an emphasis on cell & gene therapies. Cryoport enables
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with products and services that are
designed to derisk services and provide certainty. We provide
a broad array of supply chain solutions for the life sciences
industry. Through our platform of critical products and solutions
including advanced temperature-controlled packaging, informatics,
specialized bio-logistics services, bio-storage, bio-services, and
cryogenic systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at www.x.com/cryoport for
live updates.
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to
Cryoport's expectations about future benefits of the IntegriCell
solution to support the development and commercialization of cell
and gene therapies, including the potential impact on future
revenue and revenue streams. It is important to note that
Cryoport's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to, risks
and uncertainties associated with the effect of changing economic
and geopolitical conditions, supply chain constraints, inflationary
pressures, the effects of foreign currency fluctuations, trends in
the products markets, variations in Cryoport's cash flow, market
acceptance risks, and technical development risks. Cryoport's
business could be affected by other factors discussed in Cryoport's
SEC reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and Cryoport cautions investors not to place undue
reliance on these forward-looking statements. Except as required by
law, Cryoport disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-expands-integricell-cryopreservation-services-solution-with-opening-of-new-center-of-excellence-in-europe-302302519.html
SOURCE Cryoport, Inc.
